ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016
September 21 2016 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci,
Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical
Officer and Head of Research and Development, will present at The
Leerink Partners Rare Disease and Immuno-Oncology Roundtable on
September 28th, 2016, at 4:10 p.m. ET at the Lotte New York Palace
in New York, New York.
You can access the live webcast of the presentation via the
“Investors & Media” section of our website, www.arqule.com,
under “Events & Presentations”. A replay of the webcast will be
available shortly after the conclusion of the presentation.
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. Our mission is to discover, develop and commercialize
novel small molecule drugs in areas of high unmet need that will
dramatically extend and improve the lives of our patients. Our
clinical-stage pipeline consists of five drug candidates, all of
which are in targeted, biomarker-defined patient populations,
making ArQule a leader among companies our size in precision
medicine. ArQule’s lead product, in phase 3 clinical development,
is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET
receptor tyrosine kinase, for second-line treatment of
hepatocellular carcinoma in partnership with Daiichi Sankyo in the
West and Kyowa Hakko Kirin in Asia. ArQule’s proprietary pipeline
includes: ARQ 087, a multi-kinase inhibitor designed to
preferentially inhibit the fibroblast growth factor receptor (FGFR)
family, in phase 2 for iCCA and in phase 1b for multiple oncology
indications; ARQ 092, a selective inhibitor of the AKT
serine/threonine kinase, in phase 1 for multiple oncology
indications as well as ultra-rare Proteus syndrome, in partnership
with the National Institutes of Health (NIH); ARQ 751, a next
generation AKT inhibitor, in phase 1 for patients with AKT1 and
PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated
as a promoter of NQO1-mediated programmed cancer cell necrosis, in
phase 1/2 in multiple oncology indications in partnership with the
University of Texas Southwestern Medical Center. ArQule’s current
discovery efforts are focused on the identification and development
of novel kinase inhibitors, leveraging the Company’s proprietary
library of compounds.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160921005086/en/
ArQule, Inc.Dawn Schottlandt, 781-994-0300Sr. Director, Investor
Relations/Corp. Communicationswww.arqule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024